Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers.

Cabrales A, Gil J, Fernández E, Valenzuela C, Hernández F, García I, Hernández A, Besada V, Reyes O, Padrón G, Berlanga J, Guillén G, González LJ

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences23 Oct 2012Cited by 11 (Europe PMC)

PMID23099431DOI10.1016/j.ejps.2012.10.006PepBankPUB-23099431

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialPharmacokinetics
In nine healthy men, plasma GHRP‑6 stayed above the lower limit of quantification (5 ng/mL) in all subjects up to 12 hours after dosing.
In plain wordsIn nine healthy men, GHRP‑6 could be measured in blood up to 12 hours after one injection.
Peptide
GHRP-6
Outcome
Not applicablePlasma quantification window
Study
n = 9
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
100, 200 and 400 μg/kg · intravenous bolus · single doseAs given in this study (human).
Measurements
Lower limit of quantification
5 ng/mL
plasma
Time at which LLOQ was reached
12 h
post-administration, all subjects
Source sentences
Summary
The Lower Limit of Quantification (5 ng/mL) was reached in all subjects at 12h post-administration, which was sufficient for modeling a pharmacokinetic profile including over 85% of the Area under the Curve (AUC).
1 context sentence(design, population, supporting numbers)
Summary · context
In the present work, we studied the pharmacokinetics of this short therapeutic hexapeptide (His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH(2,) MW=872.44 Da) in nine male healthy volunteers after a single intravenous bolus administration of 100, 200 and 400 μg/kg of body weight.
Report a problemFND-2309943101
02HumanNon-randomized trialPharmacokinetics
In nine healthy men, GHRP‑6 disposition best fitted a bi-exponential (two-compartment) function.
In plain wordsIn nine healthy men, the body handled GHRP‑6 in two phases after injection.
Peptide
GHRP-6
Outcome
Not applicableDisposition model
Study
n = 9
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
100, 200 and 400 μg/kg · intravenous bolus · single doseAs given in this study (human).
Source sentences
Summary
Disposition of GHRP-6 best fitted a bi-exponential function with R(2) higher than 0.99, according to a mathematic modeling and confirmed by an Akaike index (AIC) lower than that of the corresponding one-compartment model for all subjects.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present work, we studied the pharmacokinetics of this short therapeutic hexapeptide (His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH(2,) MW=872.44 Da) in nine male healthy volunteers after a single intravenous bolus administration of 100, 200 and 400 μg/kg of body weight.
Report a problemFND-2309943102
03HumanNon-randomized trialPharmacokinetics
In nine healthy men, the distribution half-life of GHRP‑6 was 7.6 minutes, averaged over the three dose levels.
In plain wordsIn nine healthy men, GHRP‑6 spread through the body with a half-life of about 7.6 minutes.
Peptide
GHRP-6
Outcome
Not applicableDistribution half-life
Study
n = 9
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
100, 200 and 400 μg/kg · intravenous bolus · single doseAs given in this study (human).
Measurements
Distribution half-life
7.6 min
mean of three dose levels
Source sentences
Summary
Averaging all three dose levels, the distribution and elimination half-life of GHRP-6 were 7.6 ± 1.9 min and 2.5 ± 1.1h, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present work, we studied the pharmacokinetics of this short therapeutic hexapeptide (His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH(2,) MW=872.44 Da) in nine male healthy volunteers after a single intravenous bolus administration of 100, 200 and 400 μg/kg of body weight.
Report a problemFND-2309943103
04HumanNon-randomized trialPharmacokinetics
In nine healthy men, the elimination half-life of GHRP‑6 was 2.5 hours, averaged over the three dose levels.
In plain wordsIn nine healthy men, GHRP‑6 was cleared from the blood with a half-life of about 2.5 hours.
Peptide
GHRP-6
Outcome
Not applicableElimination half-life
Study
n = 9
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
100, 200 and 400 μg/kg · intravenous bolus · single doseAs given in this study (human).
Measurements
Elimination half-life
2.5 h
mean of three dose levels
Source sentences
Summary
Averaging all three dose levels, the distribution and elimination half-life of GHRP-6 were 7.6 ± 1.9 min and 2.5 ± 1.1h, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present work, we studied the pharmacokinetics of this short therapeutic hexapeptide (His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH(2,) MW=872.44 Da) in nine male healthy volunteers after a single intravenous bolus administration of 100, 200 and 400 μg/kg of body weight.
Report a problemFND-2309943104
05HumanNon-randomized trialPharmacokinetics
In nine healthy men, the area under the curve of GHRP‑6 tended to increase in proportion to the administered dose.
In plain wordsIn nine healthy men, higher GHRP‑6 doses gave a proportionally larger exposure in the blood.
Peptide
GHRP-6
Outcome
IncreaseDose dependence of AUC
Study
n = 9
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
100, 200 and 400 μg/kg · intravenous bolus · single doseAs given in this study (human).
Source sentences
Summary
Dose dependence analysis revealed a noticeable trend for AUC to increase proportionally with administered dose.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present work, we studied the pharmacokinetics of this short therapeutic hexapeptide (His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH(2,) MW=872.44 Da) in nine male healthy volunteers after a single intravenous bolus administration of 100, 200 and 400 μg/kg of body weight.
Report a problemFND-2309943105
06HumanNon-randomized trialPharmacokinetics
In four of nine healthy men, atypical GHRP‑6 concentration spikes appeared during the elimination phase.
In plain wordsIn four of nine healthy men, GHRP‑6 blood levels showed unexpected spikes while the drug was clearing.
Peptide
GHRP-6
Outcome
Not applicableConcentration spikes in the elimination phase
Study
n = 9
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
100, 200 and 400 μg/kg · intravenous bolus · single doseAs given in this study (human).
Source sentences
Summary
Atypical GHRP-6 concentration spikes were observed during the elimination phase in four out of the nine subjects studied.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present work, we studied the pharmacokinetics of this short therapeutic hexapeptide (His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH(2,) MW=872.44 Da) in nine male healthy volunteers after a single intravenous bolus administration of 100, 200 and 400 μg/kg of body weight.
Report a problemFND-2309943106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.